Aegerion Pharmaceuticals, a Cambridge biotech that merged last year with a Canadian firm, has finalized a $40 million settlement to resolve civil and criminal charges over its marketing of a cholesterol drug.
The U.S. Attorney’s Office in Boston said Friday that Aegerion, which is now a subsidiary of Vancouver-based Novelion Therapeutics (Nasdaq: NVLN), will plead guilty to two misdemeanor misbranding violations. The company initially disclosed last year that it expected to enter a guilty plea…
Aegerion Pharmaceuticals, a Cambridge biotech that merged last year with a Canadian firm, has finalized a $40 million settlement to resolve civil and criminal charges over its marketing of a cholesterol drug.
The U.S. Attorney’s Office in Boston said Friday that Aegerion, which is now a subsidiary of Vancouver-based Novelion Therapeutics (Nasdaq: NVLN), will plead guilty to two misdemeanor misbranding violations. The company initially disclosed last year that it expected to enter a guilty plea…